IDH1 and glioblastoma: Dose escalation cohort: Diagnosis of GBM or its histological variantsDose expansion cohort: diagnosis of GBM (or its histological variants) with IDH, BRAF, or NF1 mutations. Confirmation of these mutations may be either by immunohistochemistry or next generation sequencing.